Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PERTH, AUSTRALIA, FEB. 17, 2026 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP.(NOVO OR THE COMPANY) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) IS PLEASED TO ANNOUNCE THE RELEASE OF ITS UPDATED CORPORATE PRESENTATION, NOW AVAILABLE ON THE COMPANY'S WEBSITE.

NOVO RESOURCES RELEASES UPDATED CORPORATE PRESENTATION

THE EUROPEAN COMMISSION HAS GRANTED FINAL APPROVAL OF A HIGHER 7.2 MG MAINTENANCE DOSE OF WEGOVY (SEMAGLUTIDE) FOR ADULTS WHO MAY NEED EXTRA HELP LOSING WEIGHT. IT IS NOW APPROVED IN ALL 27 COUNTRIES IN THE EUROPEAN UNION IN A STUDY WITH 1,407 PEOPLE, LASTING ABOUT 1 YEARS, THOSE ON THE HIGHER DOSE LOST, ON AVERAGE, ABOUT ONEFIFTH OF THEIR BODY WEIGHT.

NOVO NORDISK A/S: THE EUROPEAN COMMISSION APPROVES MORE EFFECTIVE DOSE OF INJECTABLE WEGOVY FOR ADULTS WITH OBESITY; CLINICAL STUDY SHOWED PEOPLE LOST ABOUT 21% OF THEIR BODY WEIGHT ON AVERAGE

BAGSVRD, DENMARK, 16 FEBRUARY 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

BAGSVRD, DENMARK, 11 FEBRUARY 2026  THIS COMPANY ANNOUNCEMENT DISCLOSES THE DATA OF THE TRANSACTION(S) MADE IN NOVO NORDISK SHARES BY THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS IN ACCORDANCE WITH ARTICLE 19 OF REGULATION NO. 596/2014 ON MARKET ABUSE. THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS HAVE REPORTED THE TRANSACTIONS TO NOVO NORDISK.

NOVO NORDISK A/S: TRADING IN NOVO NORDISK SHARES BY BOARD MEMBERS, EXECUTIVES AND ASSOCIATED PERSONS

BAGSVRD, DENMARK, 10 FEBRUARY 2026  THIS COMPANY ANNOUNCEMENT DISCLOSES THE DATA OF THE TRANSACTION(S) MADE IN NOVO NORDISK SHARES BY THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS IN ACCORDANCE WITH ARTICLE 19 OF REGULATION NO. 596/2014 ON MARKET ABUSE. THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS HAVE REPORTED THE TRANSACTIONS TO NOVO NORDISK.

BAGSVRD, DENMARK, 9 FEBRUARY 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

NEW YORK, NY, FEB. 05, 2026 (GLOBE NEWSWIRE) -- DISCLAIMER: THIS ARTICLE IS FOR INFORMATIONAL PURPOSES ONLY. IT IS NOT MEDICAL ADVICE.

PHARMAZEE GLP-1 PRESCRIPTION INFORMATION UPDATED AS NOVO NORDISK RAISES COMPOUNDING CONCERNS AND CONSUMER INTEREST IN TELEHEALTH SEMAGLUTIDE ACCESS GROWS IN 2026

BAGSVRD, DENMARK, 5 FEBRUARY 2026  THIS COMPANY ANNOUNCEMENT DISCLOSES THE DATA OF THE TRANSACTION(S) MADE IN NOVO NORDISK SHARES BY THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS IN ACCORDANCE WITH ARTICLE 19 OF REGULATION NO. 596/2014 ON MARKET ABUSE. THE COMPANY'S BOARD MEMBERS, EXECUTIVES AND THEIR ASSOCIATED PERSONS HAVE REPORTED THE TRANSACTIONS TO NOVO NORDISK.

BAGSVRD, DENMARK AND PLAINSBORO, NJ, 5 FEBRUARY 2026  NOVO NORDISK TODAY ISSUED THE FOLLOWING STATEMENT REGARDING THE ANNOUNCEMENT BY HIMS & HERS THAT THEY WILL UNLAWFULLY MASS-MARKET AN UNAPPROVED, INAUTHENTIC, AND UNTESTED KNOCKOFF SEMAGLUTIDE PILL. THE ACTION BY HIMS & HERS IS ILLEGAL MASS COMPOUNDING THAT POSES A SIGNIFICANT RISK TO PATIENT SAFETY.

NOVO NORDISK ISSUES STATEMENT ON ILLEGAL MASS COMPOUNDING AND DECEPTIVE ADVERTISING BY HIMS & HERS

BAGSVRD, DENMARK, 4 FEBRUARY 2026  NOVO NORDISK A/S HAS FILED ITS ANNUAL REPORT 2025 ON FORM 20-F FOR THE FINANCIAL YEAR 2025 WITH THE US SECURITIES AND EXCHANGE COMMISSION (SEC), INCORPORATING BY REFERENCE PARTS OF THE NOVO NORDISK A/S ANNUAL REPORT 2025. THE REPORTS ARE AVAILABLE AT THE SEC'S WEBSITE, WWW.SEC.GOV, AS WELL AS ON NOVONORDISK.COM.

NOVO NORDISK FILES ANNUAL REPORT WITH THE SEC

BAGSVRD, DENMARK, 4 FEBRUARY 2026 THE EXECUTION OF NOVO NORDISK A/S' OVERALL SHARE REPURCHASE PROGRAMME FOR 2026 OF UP TO DKK 15 BILLION WILL BE INITIATED ON 4 FEBRUARY 2026. AS PART OF THIS, NOVO NORDISK A/S TODAY INITIATES A NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT UP TO DKK 3.8 BILLION, TO BE EXECUTED DURING THE TRADING PERIOD 4 FEBRUARY 2026 THROUGH 4 MAY 2026. THE PURPOSE OF THE PROGRAMME IS TO REDUCE THE COMPANY'S SHARE CAPITAL AND TO MEET OBLIGATIONS ARISING FROM SHARE-BASED INCENTIVE PROGRAMMES. A MAXIMUM OF 400,000,000 B SHARES OF DKK 0.10 IN TOTAL CAN BE BOUGHT DURING THE TRADING PERIOD.

NOVO NORDISK INITIATES 2026 SHARE REPURCHASE PROGRAMME

BAGSVRD, DENMARK, 4 FEBRUARY 2026 TODAY, NOVO NORDISK A/S HAS ISSUED ITS 2025 ANNUAL REPORT. THE REPORT IS AVAILABLE HERE: HTTPS://WWW.NOVONORDISK.COM/INVESTORS/ANNUAL-REPORT.HTMLAND IS ATTACHED IN IXBRL FORMAT.

NOVO NORDISK HAS PUBLISHED ITS ANNUAL REPORT FOR 2025

IN 2025, NOVO NORDISK'S SALES INCREASED BY 10% AND OPERATING PROFIT INCREASED BY 6%, COMPARED TO PREVIOUSLY ISSUED GUIDANCE OF 8 TO 11% SALES GROWTH AND

NOVO NORDISK RELEASES 2026 SALES AND OPERATING PROFIT OUTLOOK

CAGRISEMA ACHIEVED SUPERIOR WEIGHT LOSS OF UP TO 14.2%, WHERE UP TO 43% OF THE PEOPLE ACHIEVED 15% WEIGHT LOSS AND UP TO 24% ACHIEVED 20% WEIGHT LOSS1. CAGRISEMA ACHIEVED SUPERIOR HBA1C REDUCTION OF UP TO 1.91%-POINTS1 FROM A MEAN HBA1C BASELINE OF 8.2%.

NOVO NORDISK A/S: CAGRISEMA DEMONSTRATED SUPERIOR HBA1C REDUCTION OF 1.91%-POINTS AND WEIGHT LOSS OF 14.2% IN ADULTS WITH TYPE 2 DIABETES IN THE REIMAGINE 2 TRIAL

NEW YORK--(BUSINESS WIRE)--SESAME LAUNCHES WEGOVY PILL THROUGH COLLABORATION WITH NOVO NORDISK.

SESAME LAUNCHES WEGOVY PILL THROUGH COLLABORATION WITH NOVO NORDISK

BOSTON--(BUSINESS WIRE)--NOVO NORDISK TODAY ANNOUNCED THE U.S. LAUNCH OF THE WEGOVY PILL, THE FIRST ORAL GLP-1 OPTION APPROVED BY THE FOOD AND DRUG ADMINISTRATION FOR CHRONIC WEIGHT MANAGEMENT. THE INTRODUCTION OF AN ORAL FORMULATION MARKS A SIGNIFICANT STEP FORWARD IN EXPANDING PATIENT CHOICE, AND ACCESS TO EVIDENCE-BASED OBESITY TREATMENT. THE LAUNCH COINCIDES WITH AN EXPANDED NOVOCARE EXPERIENCE, DESIGNED TO HELP PATIENTS FIND TRUSTED CARE, UNDERSTAND COVERAGE OPTIONS, AND ACCESS ONGOING S.

NOVO NORDISK LAUNCHES WEGOVY PILL, EXPANDING PATIENT CHOICE AND ACCESS WITH KNOWNWELL AS A RECOGNIZED NOVOCARE PROVIDER

AVERAGE WEIGHT LOSS OF ~17% IF ALL PATIENTS STAYED ON TREATMENT* WITH WEGOVY (SEMAGLUTIDE) TABLETS 25 MG (~14% REGARDLESS OF IF PATIENTS STAYED ON TREATMENT**) IN THE OASIS 4 TRIAL1 STARTING DOSE OF WEGOVY PILL (1.5 MG) AVAILABLE TODAY FOR ONLY $149 PER MONTH (OR $5 PER DAY) VIA EASY TO ACCESS SELF-PAY OFFER WEGOVY PILL NOW BROADLY AVAILABLE THROUGH 70,000+ US PHARMACIES SUCH AS CVS AND COSTCO, SELECT TELEHEALTH PROVIDERS INCLUDING RO, LIFEMD AND WEIGHT WATCHERS, NOVOCARE  PHARMACY, GOODRX AND MORE PLAINSBORO, N.J.AND BAGSVRD, DENMARK, JAN. 5, 2026 /PRNEWSWIRE/ --WEGOVY PILL IS NOW AVAILABLE, PROVIDING THOSE SEEKING HELP WITH THEIR WEIGHT THE REVOLUTIONARY SCIENCE OF GLP-1 MEDICINE INA PILL FOR THE FIRST TIME. THIS ADVANCEMENT OPENS NEW POSSIBILITIES FOR THE MORE THAN 100 MILLION AMERICANS LIVING WITH OBESITY.2 WEGOVY PILL WAS APPROVED ON DECEMBER 22, 2025 AND IS USED WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY FOR ADULTS WITH OBESITY, OR WITH OVERWEIGHT WHO ALSO HAVE WEIGHT-RELATED MEDICAL PROBLEMS, TO HELP THEM LOSE WEIGHT AND KEEP IT OFF.3 "WE KNOW THERE ARE PEOPLE WHO ARE INTERESTED IN ADDRESSING THEIR WEIGHT BUT HAVE BEEN WAITING ON THE SIDELINES FOR A MEDICINE THAT WAS RIGHT FOR THEM.

NOVO NORDISK'S WEGOVY PILL, THE FIRST AND ONLY ORAL GLP-1 FOR WEIGHT LOSS IN ADULTS, NOW BROADLY AVAILABLE ACROSS AMERICA

TODAY, THE SUPREME PEOPLE'S COURT IN CHINA MADE A POSITIVE DECISION CONCERNING THE INTELLECTUAL PROPERTY RIGHTS RELATING TO THE SEMAGLUTIDE COMPOUND PATENT

Novo Nordisk A/S

NVO

Price

Financial Reports

No items found.

Press Releases

Novo Nordisk A/S

NVO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVO